ScreenPoint Medical

Feb. 5, 2025 — Results of a new randomized trial involving more than 105,000 women reveals that the use of artificial ...

Nov. 19, 2024 — Results of a UCLA study recently published in the Journal of Breast Imaging demonstrates that Transpara ...

May 25, 2023 — Researchers from the Mayo Clinic (Rochester, MN) and University of California, San Francisco confirmed ...

Volpara Solutions and ScreenPoint Medical BV signed an agreement under which Volpara will sell ScreenPoint's Transpara products to breast imaging clinics in the United States, Australia, New Zealand and parts of Asia. Transpara is designed to assist radiologists with the reading of mammograms and is one of the first next-generation artificial intelligence (AI) applications for detecting breast cancer in screening mammograms to gain 510(k) clearance from the U.S. Food & Drug Administration (FDA).

ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will deliver ScreenPoint’s artificial intelligence (AI)-based products to customers as part of its expanding VolparaEnterprise AI cloud ecosystem. Together, the two companies expect to improve the clinical performance of mammography and drive the earlier detection of breast cancer. The partnership will leverage Volpara’s growing footprint in the breast imaging marketplace and will provide an opportunity for ScreenPoint to enter the U.S. market.